Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate‐activated protein kinase‐related kinases and retinoid X receptor α

Shinya Satoh, Kyoko Mori, Daichi Onomura, Youki Ueda, Hiromichi Dansako, Masao Honda, Shuichi Kaneko, Masanori Ikeda, Nobuyuki Kato – 13 July 2017 – Ribavirin (RBV) has been widely used as an antiviral reagent, specifically for patients with chronic hepatitis C. We previously demonstrated that adenosine kinase, which monophosphorylates RBV into the metabolically active form, is a key determinant for RBV sensitivity against hepatitis C virus RNA replication. However, the precise mechanism of RBV action and whether RBV affects cellular metabolism remain unclear.

Increased ethanol‐inducible cytochrome P450‐2E1 and cytochrome P450 isoforms in exosomes of alcohol‐exposed rodents and patients with alcoholism through oxidative and endoplasmic reticulum stress

Young‐Eun Cho, Esteban Mezey, James P. Hardwick, Norman Salem, Dahn L. Clemens, Byoung‐Joon Song – 13 July 2017 – This study investigated the role of ethanol‐inducible cytochrome P450‐2E1 (CYP2E1) in enhancing CYP2E1 and other P450 proteins in extracellular vesicles (EVs) from alcohol‐exposed rodents and human patients with alcoholism and their effects on oxidative hepatocyte injury. Female Fischer rats and wild‐type or Cyp2e1‐null mice were exposed to three oral doses of binge ethanol or dextrose control at 12‐hour intervals.

Iron‐related markers are associated with infection after liver transplantation

Jennifer K. L. Chow, Tomas Ganz, Robin Ruthazer, Mary Ann Simpson, Elizabeth A. Pomfret, Fredric D. Gordon, Mark E. Westerman, David R. Snydman – 13 July 2017 – Though serum iron has been known to be associated with an increased risk of infection, hepcidin, the major regulator of iron metabolism, has never been systematically explored in this setting. Finding early biomarkers of infection, such as hepcidin, could help identify patients in whom early empiric antimicrobial therapy would be beneficial.

A point‐based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR‐OLT score

Lisa B. VanWagner, Hongyan Ning, Maureen Whitsett, Josh Levitsky, Sarah Uttal, John T. Wilkins, Michael M. Abecassis, Daniela P. Ladner, Anton I. Skaro, Donald M. Lloyd‐Jones – 13 July 2017 – Cardiovascular disease (CVD) complications are important causes of morbidity and mortality after orthotopic liver transplantation (OLT). There is currently no preoperative risk‐assessment tool that allows physicians to estimate the risk for CVD events following OLT.

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

Puneet Puri, Kalyani Daita, Andrew Joyce, Faridoddin Mirshahi, Prasanna K. Santhekadur, Sophie Cazanave, Velimir A Luketic, Mohammad S. Siddiqui, Sherry Boyett, Hae‐Ki Min, Divya P. Kumar, Rohit Kohli, Huiping Zhou, Phillip B. Hylemon, Melissa J. Contos, Michael Idowu, Arun J. Sanyal – 11 July 2017 – The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH.

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

Puneet Puri, Kalyani Daita, Andrew Joyce, Faridoddin Mirshahi, Prasanna K. Santhekadur, Sophie Cazanave, Velimir A Luketic, Mohammad S. Siddiqui, Sherry Boyett, Hae‐Ki Min, Divya P. Kumar, Rohit Kohli, Huiping Zhou, Phillip B. Hylemon, Melissa J. Contos, Michael Idowu, Arun J. Sanyal – 11 July 2017 – The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH.

Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease

Salvador Augustin, Mònica Pons, James B. Maurice, Christophe Bureau, Horia Stefanescu, Michel Ney, Hélène Blasco, Bogdan Procopet, Emmanuel Tsochatzis, Rachel H. Westbrook, Jaime Bosch, Annalisa Berzigotti, Juan G. Abraldes, Joan Genescà – 11 July 2017 – Patients with compensated advanced chronic liver disease (cACLD) can safely avoid screening endoscopy with a platelet count >150 × 109 cells/L and a liver stiffness measurement (LSM) <20 kPa (Baveno VI criteria). However, the total number of avoided endoscopies using this rule is relatively low.

Subscribe to